Oral GLP-1 Tablets in the UK: What You Need to Know in 2026

The question I get more than almost any other is some version of: "Is there a GLP-1 pill yet?" The answer, as of 2026, is yes. But the answer to "is it as good as the injection?" is more complicated.

Rybelsus, the oral formulation of semaglutide, has been available in the UK since 2020 and is licensed here for the treatment of type 2 diabetes. It is not licensed for obesity or weight management. It does produce weight loss. It does require a very specific way of taking it that most people get wrong. And it is less effective, on average, than the injectable version.

Here is what you actually need to know.

What Is Rybelsus?

Rybelsus is the brand name for oral semaglutide, manufactured by Novo Nordisk, the same company that makes Ozempic and Wegovy. The active ingredient is identical: semaglutide, a GLP-1 receptor agonist.

The difference is the delivery mechanism. Ozempic and Wegovy are injected once weekly via a pre-filled pen. Rybelsus is a tablet taken once daily. That sounds simpler, but the pharmacology of getting semaglutide across the gut wall and into the bloodstream is genuinely complicated.

Semaglutide is a peptide. Peptides are broken down in the stomach by digestive enzymes and by gastric acid before they can be absorbed. Injectable semaglutide bypasses this entirely. Oral semaglutide gets around it by including an absorption enhancer called sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] (SNAC), which temporarily increases gastric pH and protects the drug long enough to allow absorption across the stomach lining.

This works, but it depends on very specific conditions.

How to Take Rybelsus Correctly (and Why Most People Get It Wrong)

This is where the majority of problems with oral semaglutide occur. The dosing protocol for Rybelsus is strict in a way that injectable GLP-1s are not:

• Take the tablet first thing in the morning, on a completely empty stomach
• Swallow with no more than 120 ml (half a glass) of plain water only. No coffee, no tea, no juice
• Wait at least 30 minutes before eating, drinking anything other than water, or taking any other medications
• The tablet must not be split, crushed, or chewed

If any of these conditions are not met, absorption is significantly reduced. The SNAC absorption mechanism depends on a low-volume, water-only environment in the stomach at the time of dosing. A cup of coffee, even drunk 10 minutes after the tablet, can substantially reduce how much drug reaches circulation.

This is not a minor quibble. It is the most common reason people experience less benefit from Rybelsus than the clinical trials suggest.

Dosing Schedule

Rybelsus comes in 3 mg, 7 mg, and 14 mg tablets. The standard approach:

• Start with 3 mg daily for 30 days (a tolerability dose, not a therapeutic dose)
• Move to 7 mg daily for at least 30 days
• Increase to 14 mg daily if further glycaemic control is needed

For weight loss purposes, the 14 mg dose is the one with meaningful efficacy data. The 7 mg dose produces modest weight loss in most people.

What the Evidence Says: The SUSTAIN ORAL Trial

The key efficacy data for Rybelsus comes from the SUSTAIN ORAL trial (also known as the PIONEER programme), which compared oral semaglutide to other diabetes medications and to placebo across multiple studies.

For context on weight loss: the PIONEER 1 trial found approximately 4 kg of weight loss over 26 weeks with the 14 mg dose in people with type 2 diabetes. This compares to approximately 6 kg over the same period with once-weekly injectable semaglutide 0.5 mg (Ozempic dose) in the SUSTAIN 1 trial.

The SUSTAIN ORAL trial that directly compared oral versus injectable semaglutide is PIONEER 4:

A direct head-to-head against Ozempic is not the most prominent trial, but pooled analyses consistently show the injectable version produces approximately 1.5 to 2 kg additional weight loss over comparable periods.

Oral vs Injectable Semaglutide: A Direct Comparison

Who Is Rybelsus Licensed For in the UK?

Rybelsus is licensed in the UK for the treatment of type 2 diabetes in adults, as an adjunct to diet and exercise. It is available on the NHS for this indication, subject to prescribing criteria.

It is not licensed for obesity or weight management. Wegovy (injectable semaglutide 2.4 mg) holds that licence. This means that prescribing Rybelsus for weight loss in someone without type 2 diabetes is off-label, and NHS prescribing for this purpose is not available.

Private clinics may prescribe Rybelsus off-label for weight management. This is legal and done, but it is worth knowing you would be using it outside its licensed indication.

Who Oral GLP-1 Actually Suits

There is a genuine population for whom Rybelsus makes more sense than the injectable options:

Needle phobia. It is more common than people admit. Significant, clinically diagnosable needle phobia affects approximately 10% of the population. For these individuals, a daily tablet is not just preferable but may be the only realistic option for GLP-1 treatment.

Travel-heavy lifestyles. Injectable semaglutide needs to be refrigerated until first use, then can be stored at room temperature for up to 28 days in the pen (depending on the formulation). Crossing multiple time zones, travelling for work constantly, or spending extended periods without reliable refrigeration makes injectables logistically difficult. Tablets are simpler to transport.

People who already take morning medication. Those who have an established morning tablet routine may find it easier to add Rybelsus than to introduce a weekly injection.

Mild requirement. Someone with early type 2 diabetes who needs modest glycaemic improvement alongside modest weight loss may find the oral formulation entirely adequate for their goals.

Current NHS Availability

On the NHS, Rybelsus can be prescribed for type 2 diabetes. GPs and diabetologists can initiate this. Supply has historically been affected by the same demand issues that caused Ozempic shortages, though the situation improved through 2025.

For obesity management, Rybelsus is not an NHS option. The NHS Wegovy pathway (via specialist weight management services) is the injectable route. See the full guide on NHS Wegovy eligibility in 2026 for current criteria and waiting times.

For private prescribing of Rybelsus for weight management, costs typically run between £80 and £130 per month depending on dose and clinic. This compares to £160-250 for injectable semaglutide or tirzepatide through private channels.

Getting a Baseline Before Starting

Before starting any GLP-1 medication, including Rybelsus, it is worth having relevant baseline blood tests. This gives your prescriber a starting point and allows meaningful comparison at follow-up.

For diabetes management, the key tests are HbA1c, fasting glucose, renal function, and liver enzymes. For broader metabolic health and weight management purposes, a fuller panel is useful.

For a full guide to pre-treatment blood testing, see what blood tests to do before starting GLP-1.

Side Effects: How Oral Compares to Injectable

The side effect profile of oral semaglutide is broadly similar to injectable semaglutide, as the active drug is the same. The main differences:

• GI side effects (nausea, diarrhoea, constipation) appear to be of similar frequency and severity at comparable systemic exposures
• Because the oral route produces somewhat lower systemic drug levels at standard doses, some people experience fewer side effects, though they also experience less efficacy
• The strict dosing requirements mean accidental subtherapeutic dosing (and therefore fewer side effects) is a real risk if instructions are not followed

For a comprehensive side effect overview applicable to all semaglutide formulations, see the GLP-1 side effects guide.

Will Higher-Dose Oral GLP-1 Be Available?

Novo Nordisk has been developing a 25 mg and 50 mg oral semaglutide formulation specifically for obesity treatment, under the brand name Rybelsus OW (once weekly) or through the OASIS trial programme. The OASIS 1 trial published in 2023 showed:

A 50 mg oral formulation producing comparable weight loss to Wegovy would be significant. As of mid-2026, this formulation has not received UK regulatory approval for obesity treatment, but a regulatory submission is expected. The landscape may change in the next 12 to 18 months.

The Bottom Line

Rybelsus is a real option for people with type 2 diabetes who prefer an oral route, have needle phobia, or travel frequently. It produces meaningful weight loss and glycaemic improvement, though modestly less than the injectable equivalent.

For obesity treatment without diabetes, it is not currently licensed in the UK, and the efficacy gap compared to Wegovy at standard doses is clinically meaningful. Higher-dose oral semaglutide may close this gap when it reaches UK approval.

If you are considering a GLP-1 medication and trying to choose between oral and injectable routes, see also the Mounjaro vs Wegovy comparison for women, which covers the broader landscape of available medications.